CTI: Tosedostat- Cytarabine Combination Meets Primary Goal In Phase 2 AML Study

(RTTNews) - CTI BioPharma Corp. (CTIC) Monday announced that Tosedostat in combination with low dose Cytarabine achieved primary endpoint in phase 2 study in elderly patients with acute myeloid leukemia or AML.

CTI announced findings from an investigator-sponsored Phase 2 trial in patients with either primary AML or AML that has evolved from myelodysplastic syndrome or MDS. Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML - with 45 percent of patients achieving durable complete responses.

These final results were presented by Giuseppe Visani, Director of Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy in a poster session during the 20th Congress of the European Hematology Association, June 11-14, 2015 in Vienna, Austria.

AML is the most common acute leukemia affecting adults, and its incidence increases with age. Tosedostat is a potential first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival.